Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/tazobactam + metronidazole vs meropenem in complicated intra-abdominal infection (China)
CTR20170435Phase 3Completed
- Sponsor
- Merck Sharp & Dohme Ltd.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in Intra-abdominal infection (IAI), sponsored by Merck Sharp & Dohme Ltd.. Started Dec 2018; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on CTR20170435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170435.